Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMP-3124LP in Advanced Solid Tumors
NCT06526819Phase 2Recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Countries
- 2
01
Overview
Phase 2, open-label trial of smp-3124lp in solid tumor (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 6 months and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
smp-3124lp
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06526819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526819.